Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MercadoLibre (MELI) upgraded to Overweight from Neutral at JPMorgan by analyst Andre Baggio, who said the Brazilian marketplace is thriving, and MercadoLibre is gaining market share. 2. Teva (TEVA) upgraded to Outperform from Perform at Oppenheimer by analyst Rohit Vanjani, who points out that the validity of Teva's Copaxone patents now lies with the District Court decision after the inter partes reviews by the USPTO. Vanjani believes the court ruling, which will likely come in early 2017, is the more important of the two, with a higher hurdle to invalidate the patents. 3. Pioneer Energy (PES) upgraded to Buy from Hold at Jefferies by analyst Brad Handler, who argues that the 24% pullback in shares since the early July peak provides an attractive valuation. The analyst believes Pioneer's covenant risk can be managed and raised his price target for the shares to $6 from $5. 4. Amec Foster Wheeler (AMFW) upgraded to Buy from Neutral at BofA/Merrill. 5. Mitsubishi UFJ (MTU) upgraded to Outperform from Neutral at Daiwa. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."